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damage response, immune/inflammatory response, or cell 
signaling processes; however, the type of pathways and the 
magnitude of change varied for each PAH and were not the 
same as those observed for BaP. Benchmark dose modeling 
showed transcriptomic data closely reflected the known 
tumor incidence for the individual PAHs in each tissue. 
Collectively, the results suggest that the underlying mecha-
nisms of PAH-induced toxicity leading to tumorigenesis 
are tissue-specific and not the same for all PAHs; based on 
the tissue type considered, use of BaP as a reference chemi-
cal may overestimate or underestimate the carcinogenic 
potential of PAHs.
Keywords Polycyclic aromatic hydrocarbons · 
Toxicogenomics · Mode of action · Benzo(a)pyrene · 
Complex mixtures
Introduction
Many regulatory agencies recommend the use of a refer-
ence chemical approach to assess the hazards posed by 
chemical mixtures in complex environmental matrices 
(EFSA 2008; Health Canada 2010; Health Protection 
Agency 2010; USEPA 2010). For example, the current 
human health risk assessment approach for evaluating the 
carcinogenic risks of soils contaminated with mixtures of 
polycyclic aromatic hydrocarbons (PAHs) involves exami-
nation of the cumulative risk posed by a targeted set of 
PAHs. Benzo(a)pyrene (BaP) is the most extensively stud-
ied of the carcinogenic PAHs and is used as the point of 
reference for the carcinogenic potency of the other PAHs.
Human health risk assessment of PAH-contaminated 
complex environmental mixtures considers the incremental 
carcinogenic risk of a targeted set of PAHs as toxicological 
Abstract In this study, the accuracy of the assumption 
that genotoxic, carcinogenic polycyclic aromatic hydro-
carbons (PAHs) act via similar mechanisms of action as 
benzo(a)pyrene (BaP), the reference PAH used in the 
human health risk assessment of PAH-containing com-
plex mixtures, was investigated. Adult male Muta™Mouse 
were gavaged for 28 days with seven individual, genotoxic 
PAHs. Global gene expression profiles in forestomach, 
liver, and lung (target tissues of exposure) were deter-
mined at 3 days post-exposure. The results are compared 
with our previously published results from mice exposed 
to BaP via the same exposure regimen. Although all PAHs 
showed enhanced ethoxyresorufin-O-deethylase activity, 
DNA adduct formation, and lacZ mutant frequency in the 
lungs, the unsupervised cluster analysis of differentially 
expressed genes revealed that the transcriptional changes 
are both PAH- and tissue-specific, with lung showing the 
most response. Further bioinformatics-/pathway-based 
analysis revealed that all PAHs induce expression of genes 
associated with carcinogenic processes, including DNA 
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equivalents of BaP (relative potency factor approach). 
However, to be able to apply this approach, all structur-
ally similar PAHs in a mixture must elicit similar toxico-
logical responses via similar modes/mechanisms of action. 
The most well-established mode of action of genotoxic, 
carcinogenic PAHs involves binding and activating the 
aryl hydrocarbon receptor (AhR), the expression of genes 
associated with xenobiotic metabolism, and the concur-
rent metabolism of PAHs. This in turn leads to the pro-
duction of reactive intermediates (e.g., diol epoxides) that 
covalently bind DNA and form bulky DNA adducts. When 
left unrepaired, these DNA adducts can result in muta-
tions in tumor-suppressor genes or oncogenes, which can 
eventually lead to carcinogenesis, implying a genotoxic 
mode of action in cancer. Consequently, measurement of 
DNA adducts and DNA mutations have long been taken 
as measurable markers of the genotoxic mode of action of 
PAHs. However, the existing toxicological database (show-
ing evidence for carcinogenicity and the details pertinent 
to the underlying mechanisms of carcinogenicity) for the 
individual PAHs is incomplete and thus lacks experimen-
tal support for the use of the reference chemical method 
(Bostrom et al. 2002). In order to strengthen the application 
of the reference chemical approach, the USEPA (USEPA 
2010) has outlined certain considerations that are important 
for PAH mixture cancer risk assessment, which includes a 
detailed characterization of toxicological responses elicited 
by individual PAHs in the mixture.
Recent work from our laboratory examined the lev-
els of DNA damage, mutation, and global gene expres-
sion changes in the forestomach (Labib et al. 2013), liv-
ers (Malik et al. 2012), and lungs (Labib et al. 2012) of 
Muta™Mouse males exposed to BaP by oral gavage for 
28 consecutive days. The results of these studies revealed 
that (1) the levels and relationship between bulky DNA 
adducts and transgene mutant frequencies differ between 
tissues, and (2) BaP-induced alterations in gene/protein 
expression associated with a diverse array of cellular sign-
aling pathways/biological functions, including carcinogen-
esis and the magnitude of change, varied between the tis-
sues. Moreover, compared to the amount of DNA damage 
and mutations, the observed extent of the transcriptomic 
response was more closely related to previously reported 
tumor incidence in each of these tissues (Hakura et al. 
1998). These results suggest that the carcinogenic potency 
and the underlying mode of action (including metabolism, 
DNA damage, mutation, and pathway perturbations) for 
BaP differs based on the type of tissue investigated. These 
results also implied that the current approach of human 
health risk assessment, which assumes that the toxicologi-
cal activities of PAHs reflect a single mode of action, may 
be overgeneralized.
In the present study, we sought to explore the underlying 
carcinogenic modes of action of several individual PAHs 
to specifically investigate whether the assumption of simi-
lar mode of action is accurate. We exposed Muta™Mouse 
males to three doses of seven PAH congeners or vehicle for 
28 consecutive days via oral gavage. These seven PAHs are 
known to be genotoxic and constitute the panel of PAHs 
recommended for routine measurement in contaminated 
soils for the protection of human and environmental health 
in the Canadian soil quality guidelines (CCME 2010) and 
in contaminated food samples (EFSA 2008). Forestomach, 
livers, and lungs were collected 3 days after the final expo-
sure, and DNA microarrays were employed to generate the 
gene expression profiles of these tissues. The results were 
compared to gene expression profiles in forestomach, liv-
ers, and lungs of mice previously exposed to BaP (Labib 
et al. 2012, 2013; Malik et al. 2012). The data were used to 
(a) identify the cancer-associated biological functions and 
pathways affected following exposure to different PAHs, 
(b) evaluate the assumption that all structurally similar 
PAHs with similar toxicological outcome (i.e., cancer) act 
via the same mode of action, and (c) determine whether 
BaP as a reference chemical appropriately represents the 
toxicity of the other seven PAHs. In addition to the gene 
expression profiling, DNA adducts and lacZ transgene 
mutant frequencies were measured in lungs to confirm the 
genotoxic phenotype, and activation of metabolic enzymes 
in the lungs of mice was measured using the ethoxyresoru-
fin-O-deethylase (EROD) assay.
Methods
Materials and dose selection
Seven PAHs were individually analyzed in this study: 
benz(a)anthracene (BaA), benzo(b)fluoranthene (BbF), 
benzo(g,h,i)perylene (BghiP), benzo(k)fluoranthene (BkF), 
dibenz(a,h)anthracene (DBahA), indeno(123-c,d)pyrene 
(IP) (Cambridge Isotopes Laboratories, USA), and chrysene 
(Chr) (Sigma-Aldrich Canada Ltd, Canada). All of these 
PAHs are classified as possible or probable human car-
cinogens by IARC and the USEPA (IARC 2010; USEPA 
2011), except for BghiP which is classified as a genotoxic 
PAH. Maximum doses were initially selected based on 
the maximum tolerated dose of each PAH in a dose-range 
finding study. This dose was diluted two times, twofold, to 
obtain two lower doses, except for Chr, which was diluted 
threefold. The specific doses were as follows: BaA (20, 
40, 80 mg/kg-bw/day), BbF (25, 50, 100 mg/kg-bw/day), 
BghiP (6.25, 12.5, 25 mg/kg-bw/day), BkF (25, 50, 100 mg/
kg-bw/day), Chr (17.5, 50, 150 mg/kg-bw/day), DBahA 
(6.25, 12.5, 25 mg/kg-bw/day), and IP (12.5, 25, 50 mg/
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kg-bw/day). The results are compared to data derived from 
experiments using an identical experimental design for BaP 
exposures (25, 50, 75 mg/kg-bw/day); results from the BaP 
study were published in Malik et al. (2012) and Labib et al. 
(2012, 2013). Data from DBahA-exposed livers were also 
published previously in Malik et al. (2013).
Muta™Mouse exposures
Animal care, exposures, and tissue collection procedures 
were described previously (Labib et al. 2012; Lemieux 
et al. 2011). In brief, adult male Muta™Mouse (transgenic 
mouse strain 40.6) were exposed by oral gavage for 28 con-
secutive days to olive oil (vehicle control) or three doses of 
the seven individual PAHs dissolved in olive oil, according 
to the established Organization for Economic Co-operation 
and Development (OECD) guideline for transgenic rodent 
mutation assays (OECD 2011). Each treatment group con-
tained five animals. Mice were killed by cardiac puncture 
under isofluorene anesthesia 3 days after the final exposure. 
No mice showed overt signs of toxicity during the expo-
sure period. Five mice from the BkF group and one from 
the IP group died as a result of accidental pulmonary punc-
ture during oral gavage. Thus, the final sample size for BkF 
was 4, 3, 4, and 4 in the control, low-, medium-, and high-
dose groups, respectively, at necropsy. The IP control group 
consisted of only 4 mice at necropsy. The forestomach, 
left lobe of the liver, and the right lobe of the lung were 
collected, flash-frozen in liquid nitrogen, and stored at 
−80 °C until use. Mice were bred, maintained, and treated 
in accordance with the Canadian Council for Animal Care 
Guidelines, and all protocols were approved by Health 
Canada’s Animal Care Committee.
Tissue RNA extraction and purification
Total RNA was isolated for gene expression analysis using 
TRIzol reagent (Invitrogen, Canada) and RNeasy Mini 
Kits following the protocols previously published (Halap-
panavar et al. 2011; Labib et al. 2012, 2013). For detailed 
description of methods, please see Online Resource 1A.
Microarray hybridization and analysis
RNA samples were hybridized to Agilent Sureprint G3 
Mouse GE 8 × 60 K microarrays (Agilent Technolo-
gies, Canada) following previously published protocols 
(Labib et al. 2013; Malik et al. 2012) and scanned on the 
Agilent G2505B scanner. Sample sizes of 5 were used for 
each treatment and control group, except for the BkF and 
IP exposures. LOWESS was used to normalize the sig-
nal intensities, MAANOVA was used to identify differ-
entially expressed genes, and multiple comparisons were 
adjusted for using the false discovery rate (FDR) approach, 
as described in Labib et al. (2013) (Online Resource 1B). 
All microarray results were deposited in the Gene Expres-
sion Omnibus database (http://www.ncbi.nlm.nih.gov/geo/) 
under the accession number GSE51321. Differentially 
expressed genes (DEGs) were defined as genes with FDR-
adjusted P values less than 0.05 (FDR P ≤ 0.05) from the 
pairwise analysis to controls with absolute fold change esti-
mates greater than or equal to 1.5 in either direction (fold 
change ±1.5). Hierarchical cluster analysis was applied to 
the filtered data and visualized using a heatmap using R (R 
Development Core Team 2010) (Online Resource 1C).
Bioinformatics and pathway analysis
The lists of DEGs (FDR P ≤ 0.05, fold change ±1.5) 
from each PAH were independently analyzed to identify 
biological functions or processes perturbed in response to 
the treatment. DAVID (Huang da et al. 2009) Functional 
Annotation Charts were used to identify gene ontology 
(GO) terms (biological processes and cellular compart-
ments) associated with the significant genes and to classify 
the DEGs into biological pathways using KEGG pathways 
(Kanehisa and Goto 2000). MetaCore (Thomson Reuters, 
http://www.genego.com/metacore.php) pathway analy-
sis and network process analysis were used for functional 
classification. The canonical pathway analysis, biological 
function analysis, and network analysis within Ingenuity 
Pathway Analysis (IPA, Ingenuity Systems, Redwood City, 
CA) were used to identify biological pathways and func-
tions associated with the DEGs. Since there was a large 
redundancy in the annotation of the perturbed biological 
processes, pathways, and functions, the results were fur-
ther grouped under parent pathways/processes (Online 
Resource 2). IPA’s Upstream Regulator analysis was per-
formed to determine the regulatory mechanisms (tran-
scription factors and receptors) operating in response to 
individual PAHs, and these were compared to BaP. Online 
Resource 1D describes the criteria used to determine the 
statistical significance of altered pathways, functions, bio-
logical processes, or upstream regulators.
The NextBio meta-analysis function (http://nextbio.
com) was used to compare the transcriptomic responses 
following exposure to individual PAHs and following expo-
sure to BaP. A less stringent non-FDR P value cutoff of less 
than 0.05 and a fold change of ±1.2 was applied. A pair-
wise comparison was made for each gene between the two 
datasets (for example, BaP vs BbF). A rank-based enrich-
ment statistic was applied to determine the final correlation 
score. If the direction of change in the expression of a gene 
following exposure to a congener PAH was the same as the 
direction of change in expression of that gene following 
exposure to BaP, then the correlation was positive.
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Since the focus of the study was to compare the carci-
nogenic potential of PAHs, significantly perturbed path-
ways and processes were reorganized according to their 
association with the six hallmarks of cancer (activating 
invasion and metastasis, enabling replicative immortal-
ity, evading growth suppressors, inducing angiogenesis, 
resisting cell death, sustained proliferative signaling), 
two emerging hallmarks (deregulating cellular energet-
ics, avoiding immune destruction), and two enabling 
characteristics (genome instability and mutation, tumor-
promoting inflammation), as described in Hanahan and 
Weinberg (2011). Re-classification was determined 
by conducting a literature review using search terms 
related to each significant pathway and each hallmark 
of cancer. Pathways or processes that could not be clas-
sified as cancer-related using these criteria were not 
used in the subsequent analysis and interpretation of the 
results.
DNA extraction from lung tissue
Frozen lung tissues were sliced randomly for isolation 
of genomic DNA by phenol/chloroform extraction as 
described previously (Labib et al. 2012; Renault et al. 
1997) (Online Resource 1E).
LacZ mutant frequency in lung tissue
The lacZ mutant frequency analysis in lung tissues using 
the phenyl-β-d-galactopyranoside (P-Gal)-positive selec-
tion assay was conducted as described previously (Labib 
et al. 2012; Lemieux et al. 2011) (Online Resource 1F). 
Mutant frequency was expressed as the ratio of mutant 
plaque forming units to total plaque forming units.
DNA adduct analysis in lung tissue
DNA adduct formation in each sample was determined 
using the nuclease P1 digestion enrichment version of 
the 32P-post-labeling assay as described previously 
(Phillips and Arlt 2007, 2014) with minor modifica-
tions described in Labib et al. (2012) (Online Resource 
1G). The results are expressed as DNA adducts per 108 
nucleotides.
Enzymatic analysis of lung Cyp1a activity
Enzymatic analysis of pulmonary CYP1A activity was 
assessed via the ethoxyresorufin-O-deethylase (EROD) 
assay. Since the available amount of tissue from each treat-
ment group was small, samples from the same treatment 
group were pooled (Online Resource 1H).
Benchmark dose (BMD) calculations
BMD and BMDL (lower confidence limit of BMD) values 
were modeled for apical endpoint measurements (EROD 
activity, DNA adduct formation, lacZ mutant frequency) 
in lungs. Further, BMDs were modeled for the total num-
ber of DEGs, the number of DEGs related to the hallmarks 
of cancer, and for the number of hallmarks of cancer per-
turbed by each PAH in the forestomach, liver, and lung tis-
sues using the USEPA’s Benchmark Dose software BMDS 
version 2.5.0 (http://www.epa.gov/ncea/bmds/) (Davis 
et al. 2011). Continuous data were run against five mod-
els (Exponential, Hill, Power, Polynomial, and Linear), 
and proportional (dichotomous) data were run against eight 
models (Gamma, Logistic, LogLogistic, Probit, LogPro-
bit, Weibull, Multistage, QuantalLinear). The benchmark 
response (BMR) was set to 10 % extra risk as recom-
mended by the Benchmark Dose Technical Guidance docu-
ment (USEPA 2012). The best model for each dataset was 
selected based on the lowest Akaike’s information criterion 
(AIC) value, excluding models with BMD greater than the 
highest dose, BMD/BMDL ratios >10, and goodness of fit 
P < 0.1.
Results
Adult male Muta™Mouse were exposed to three doses of 
individual PAHs (BaA, BbF, BghiP, BkF, Chr, DBahA, or 
IP) for 28 consecutive days via oral gavage. The exposure 
regimen did not cause any overt signs of toxicity, and there 
was no significant body weight loss in any of the exposed 
mice compared to vehicle-treated controls. Forestomach, 
liver, and lung tissues were collected 3 days after the final 
exposure.
General overview of the microarray results
The transcriptomic profiles derived from the present study 
were compared with the profiles of mice exposed to BaP 
(following the same exposure regimen described for other 
seven PAHs in this study) to investigate whether BaP, as a 
reference PAH, accurately represents the toxicity posed by 
other individual PAHs. Global transcriptomic changes in 
the forestomach, liver, and lung tissue were characterized.
Table 1 summarizes the total number of DEGs (FDR 
P ≤ 0.05, fold change ±1.5) for each tissue and the dif-
ferent doses tested. Online Resource 3 provides the full 
lists of DEGs including the gene names, gene accession 
numbers, P values, and fold changes for the forestomach, 





Responses to each individual PAH were analyzed sepa-
rately, and the results were then compared across all 
PAHs. Of all the PAHs tested, BaP induced the largest 
response in forestomach. Hierarchical cluster analysis 
was conducted using 1008 DEGs that showed differential 
expression in at least one dose group for at least one PAH 
Table 1  Total numbers of 
differentially expressed genes 
in forestomach, liver, and lung 
tissues
Gene expression profiles for BaP in the forestomach, liver, and lung were previously published* (Labib 
et al. 2012, 2013)
BaP* BaA BbF BghiP BkF Chr DBahA IP
1. Forestomach
 Low
  Up 9 10 0 0 1 3 0 0
  Down 0 0 2 3 0 2 0 2
  Total 9 10 2 3 1 5 0 2
 Med
  Up 119 3 2 4 7 37 1 0
  Down 16 2 2 8 128 17 2 1
  Total 135 5 4 12 135 54 3 1
 High
  Up 311 5 15 95 12 166 3 5
  Down 97 11 6 14 143 52 2 3
  Total 408 16 21 109 155 218 5 8
 Total 414 27 23 119 213 244 6 9
2.  Liver
 Low
  Up 2 7 16 2 5 2 29 0
  Down 3 70 5 3 1 2 27 0
  Total 5 77 21 5 6 4 56 0
 Med
  Up 9 22 122 2 96 3 20 1
  Down 1 172 37 2 28 3 37 5
  Total 10 194 159 4 124 6 57 6
 High
  Up 109 51 201 20 111 3 188 6
  Down 21 163 83 40 58 1 121 13
  Total 130 214 284 60 169 4 309 19
 Total 139 340 352 69 224 13 334 24
3.  Lung
 Low
  Up 14 22 219 1 7 3 165 6
  Down 3 7 37 1 3 3 27 25
  Total 17 29 256 2 10 6 192 31
 Med
  Up 104 152 222 27 61 0 254 41
  Down 22 40 131 9 55 1 46 120
  Total 126 192 353 36 116 1 300 161
 High
  Up 240 409 586 51 91 92 415 140
  Down 77 214 340 12 108 67 151 132
  Total 317 623 926 63 199 159 566 272
 Total 329 675 1136 84 248 162 624 319
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(Fig. 1a). The analysis revealed that the samples generally 
clustered first by PAH (with dose groups together) rather 
than by dose. BaP clustered along with BbF and BaA (1) 
on one branch. Chr, DBahA, and IP clustered on a sepa-
rate branch (2). However, there was no clear clustering 
observed for BghiP and BkF, which were scattered between 
the two branches. A VENN analysis of the DEGs from all 
PAHs revealed that there were no genes in common to all 
PAHs studied, supporting the results of the cluster analy-
sis. The number of DEGs common between BaP and the 
other PAHs tested was as follows: 5 for BaA, 8 for BbF, 4 
for BghiP, 7 for BkF, 9 for Chr, 0 for DBahA, and 1 for IP 
(Fig. 1b). Figure 1b also shows the genes in common for 
each pairwise comparison across all of the PAHs, revealing 
remarkably little in common.
In addition to comparison of DEGs by VENN analysis, a 
meta-analysis of all datasets was conducted using NextBio. 
Since most of the PAHs induced very subtle responses at the low 
or medium doses, the meta-analysis was conducted on the high-
dose groups of each PAH (Fig. 1c). This analysis employed a 
less stringent statistical model (ANOVA P ≤ 0.05) compared to 
the FDR-adjusted P value approach and used a ranking of genes 
based on their fold changes to explore the correlation of the 
trends in gene ranking. The results revealed a strong correlation 
between BaP, BbF, and BaA, whereas BghiP and IP were least 
correlated with BaP. Chr was negatively correlated with BaP.
Fig. 1  Forestomach a hierarchical cluster analysis comparing fores-
tomach gene expression data from adult male Muta™Mouse exposed 
to three doses (low—L, medium—M, high—H) of eight PAHs. 
Branches are color coded for PAH treatment. Genes were included if 
they reached significance (FDR P ≤ 0.05, fold change ±1.5 in either 
direction) in at least one treatment group. Groups represent an aver-
age of all mice in one group. b Table of forestomach DEGs that are 
common in at least one dose group. Cells highlighted in gray rep-
resent the total number of DEGs for that PAH. c Degree of correla-
tion between BaP DEGs and DEGs for each PAH in the forestomach 
using the NextBio Meta-analysis tool. The height of each vertical 
bar represents the degree of correlation between the PAH and BaP 
[−log(P value)], which is associated with the directionality of the 
gene expression changes. Red color denotes positive correlation with 
BaP, and green color denotes negative correlation. d All pathways 
significantly enriched for by BaP in the forestomach and the com-
monalities with other PAHs. Each column represents a dose group for 
the denoted PAH, and each row represents a gene. All colored cells 
represent genes with fold change ≥1.5 in either direction. e Pertur-
bation of the hallmarks of cancer, emerging hallmarks, and enabling 
characteristics by each PAH in the forestomach based on transcrip-
tomic data. The purple cells represent the relative contribution of 




Similarities in the forestomach response relative 
to BaP Figure 1d summarizes the molecular pathways, bio-
logical processes, and molecular functions that are altered in 
forestomach following exposure to BaP as compared to the 
other seven PAHs. This analysis includes all significantly 
altered gene ontologies (EASE P ≤ 0.05), KEGG pathways 
(EASE P ≤ 0.05), IPA canonical pathways (P ≤ 0.05), and 
MetaCore process networks (P ≤ 0.05). Since there was 
a large redundancy in the annotation of the perturbed bio-
logical processes, pathways, and functions, the results were 
further grouped under parent pathways/processes (Online 
Resource 1).
Five main functional categories of pathways and pro-
cesses were perturbed in forestomach following exposure 
to BaP: DNA damage response, altered cell signaling, 
immune and inflammatory response, altered metabolism, 
and cytoskeletal organization (Fig. 1d). Specifically, in the 
DNA damage response, DEGs were mainly associated with 
p53 signaling; AhR signaling, endocytosis, epithelial cell 
differentiation, and ubiquitination were the predominant 
pathways under altered cell signaling; xenobiotic metabo-
lism, glutathione metabolism, melatonin degradation, and 
estrogen biosynthesis were related to altered metabolism, 
and cell division control protein 42 homolog (CDC42) 
signaling was the most significantly affected under the 
cytoskeletal organization category. The immune/inflam-
matory response category was the most enriched, and the 
DEGs were mainly associated with antigen processing and 
presentation, pattern recognition receptors, innate to adap-
tive immune cell communication (immune cell communi-
cation), interferon signaling, OX40 signaling, cytotoxic T 
cell signaling, TREM1 signaling, cytokine–cytokine recep-
tor interaction, and nod-like receptor (NLR) signaling.
To focus on the cancer mode of action, pathway pertur-
bations that functioned in processes related to the published 
hallmarks of cancer were examined in detail (Hanahan 
and Weinberg 2011). Specifically, the number and types 
of pathways associated with the hallmarks of cancer that 
were perturbed by each PAH were compared to BaP. In the 
forestomach, BaP exposure perturbed all ten hallmarks of 
cancer across all doses (Fig. 1e). The number of pathways 
associated with each hallmark ranged from one to five; the 
five pathways were associated with the emerging hallmark 
“avoiding immune destruction” and the enabling character-
istic of “tumor-promoting inflammation.”
Of the 20 distinct biological pathways altered in 
response to BaP, only endocytosis was perturbed by more 
than one PAH (BghiP and BkF). Other BaP-perturbed path-
ways such as ubiquitination, antigen processing and pres-
entation (APP), pattern recognition receptors, xenobiotic 
metabolism, and epithelial cell differentiation were altered 
following exposure to BaA, BbF, BbF, or BkF, respectively. 
Chr, DBahA, and IP did not have any pathways in common 
with BaP. We note that although endocytosis was altered 
by both BaP and BkF treatment, the direction of change 
was different; endocytosis appeared to be upregulated fol-
lowing BaP exposure and downregulated following BkF 
exposure, suggesting that the final toxic outcome of this 
change may be different for these PAHs (Fig. 2a). Other 
examples of discrepancies in pathway regulation include 
epithelial cell differentiation (BaP↑, BkF↓) and protein 
ubiquitination (BaP↑, BaA↓). It was difficult to determine 
the directionality of change of endocytosis in BghiP, since 
50 % of DEGs in this group suggested upregulation of the 
pathway and 50 % suggested downregulation. Compared to 
the BaP-induced response, BaA perturbed only two hall-
marks of cancer, with one altered pathway each; BbF per-
turbed seven hallmarks of cancer with one to two pathways 
each; Chr perturbed five hallmarks of cancer with one to 
five pathways each, the strongest response associated with 
“activating invasion and metastasis”; DBahA and IP did not 
perturb any hallmarks.
We performed an Upstream Regulator Analysis in IPA to 
identify upstream biological molecules (transcription fac-
tors, membrane receptors, cytokines, etc.) responsible for 
regulating the expression of DEGs (Online Resource 4) in 
the forestomach for each of the PAHs. Very few commonal-
ities were observed between BaP and the other PAHs. The 
results suggest that the transcriptomic changes induced in 
forestomach by each of the PAHs are mediated by different 
regulatory molecules.
Differences in the forestomach response relative 
to BaP Figure 2b shows a range of cellular processes and 
functions including thrombin signaling, estrogen receptor 
signaling, transcription, and extracellular membrane inter-
actions that were not altered by BaP, but were altered by 
exposure to at least one of the other PAHs. Indeed, several 
pathways (e.g., retinoid X receptor (RXR) activation, lipid 
metabolism, and integrin signaling) were altered in response 
to more than one PAH. However, the relevance of these 
pathways to cancer formation in forestomach is unclear.
Hepatic transcriptional response
Of the PAHs tested, BbF, BaA, and DBahA induced the 
most changes in hepatic gene expression. Hierarchical clus-
ter analysis was conducted using 977 DEGs that were dif-
ferentially expressed in at least one dose group for at least 
one PAH. Cluster analysis revealed that each PAH clus-
tered separately, suggesting PAH-specific transcriptomic 
responses in the liver (Fig. 3a). Except for the high dose of 
BbF, each PAH clustered along with the other dose groups 
for that PAH. Three main clusters were observed: cluster 1 
consisting of BaP, cluster 2 consisting of BkF, IP, BbF, and 
DBahA, and cluster 3 consisting of BaA, Chr, and BghiP. 
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Similar to the forestomach results, a VENN analysis of all 
hepatic DEGs revealed that there were no genes in common 
to all the PAHs studied. The number of DEGs that were in 
common between BaP and the other PAHs included: 10 for 
BaA, 30 for BbF, 2 for BghiP, 9 for BkF, 1 for Chr, 11 for 
DBahA, and 2 for IP (Fig. 3b). Figure 3b also shows the 
genes in common for each pairwise comparison across all 
of the PAHs, revealing little in common.
A meta-analysis of all DEGs from the high-dose group 
of all the PAHs was conducted in NextBio (Fig. 3c). Tran-
scriptomic profiles of BbF and BaP showed a strong posi-
tive correlation, whereas BkF, DBahA, and IP did not cor-
relate with BaP. BaA and Chr were negatively correlated 
with BaP.
Similarities in the hepatic response relative to BaP BaP-
induced hepatic transcriptomic responses were function-
ally separated into four main categories of pathways and 
processes: DNA damage response, altered cell signaling, 
immune and inflammatory response, and altered metabolic 
signaling. Category 1 (DNA damage response) DEGs were 
mainly associated with p53 signaling. Category 2 (cell sign-
aling pathways) included DEGs associated with RXR, AHR, 
nuclear factor-like 2 (NRF2), peroxisome proliferator-acti-
vated receptors (PPAR), phosphate and tensin homolog 
(PTEN), nuclear factor kappa light-activated enhancer of 
activated B cells (NFkB), lipid, signal transducer and activa-
tor of transcription 3 (STAT3), and 5′ adenosine monophos-
phate-activated protein kinase (AMPK) signaling pathways. 
Subcategories of cell signaling pathways related to immune/
inflammatory response (Category 3) such as acute phase 
response, T helper cell signaling, and interleukin signaling 
were also altered. Category 4 (metabolic signaling path-
ways) included xenobiotic metabolism, glutathione metab-
olism, and retinol metabolism. In the liver, BaP exposure 
activated all ten hallmarks of cancer (Fig. 3e). The number 
Fig. 2  Forestomach a honeycomb diagram showing direction of reg-
ulation of pathways commonly enriched for by BaP and other PAHs. 
Orange honeycombs represent pathways that are predicted to be acti-
vated based on the direction of regulation of the genes, and blue cells 
represent those predicted to be inhibited. Black cells represent those 
in which 50 % of the genes indicate activation and 50 % of the genes 
indicate inhibition. White cells represent pathways not significant. 
b Pathways enriched for by at least one PAH and not by BaP. Each 
column represents a dose group for the denoted PAH and each row 
represents a gene. All colored cells represent genes with fold change 
≥1.5 in either direction (color figure online)
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of pathways associated with each hallmark ranged from one 
to five; the five pathways were associated with “sustained 
proliferative signaling” and the enabling characteristic of 
“tumor-promoting inflammation”.
Of the 16 biological pathways altered in response to 
BaP, RXR signaling and xenobiotic metabolism were 
commonly perturbed by three other PAHs (BbF, BkF, and 
DBahA). Pathways common to two other PAHs included 
p53 signaling, AHR signaling, and retinol metabolism 
common to BbF and BkF, and lipid signaling common to 
BbF and DBahA. Although the p53 signaling pathway was 
altered following treatment with BaP, BbF, and BkF, it was 
upregulated in response to BaP, whereas it was downregu-
lated in response to BbF and BkF (Fig. 4a). For many other 
pathways, it was difficult to determine the directionality 
of change: RXR activation (BaP↑, BbF↕), lipid signaling 
(BaP↑, DBahA↕), xenobiotic metabolism signaling (BaP↑, 
BbF↕), and retinol metabolism (BaP↑, BbF↕). Six upstream 
regulators were identified that were common to three of the 
PAHs including BaP (Online Resource 4). BbF, BkF, and 
Fig. 3  Liver a hierarchical cluster analysis comparing hepatic gene 
expression data from adult male Muta™Mouse exposed to three 
doses (low—L, medium—M, high—H) of eight PAHs. Branches are 
color coded for PAH treatment. Genes were included if they reached 
significance (FDR P ≤ 0.05, fold change ±1.5 in either direction) in 
at least one treatment group. Groups represent an average of all mice 
in one group. b Table of hepatic DEGs that are common in at least 
one dose group. Cells highlighted in gray represent the total number 
of DEGs for that PAH. c Degree of correlation between BaP DEGs in 
the liver and DEGs for each PAH in the liver using the NextBio Meta-
analysis tool. The height of each vertical bar represents the degree 
of correlation between the PAH and BaP [−log(P value)], which is 
associated with the directionality of the gene expression changes. Red 
color denotes positive correlation with BaP, and green color denotes 
negative correlation. d All pathways significantly enriched for by BaP 
in the liver and the commonalities with other PAHs. Each column 
represents a dose group for the denoted PAH and each row repre-
sents a gene. All colored cells represent genes with fold change ≥1.5 
in either direction. e Perturbation of the hallmarks of cancer, emerg-
ing hallmarks, and enabling characteristics by each PAH in the liver 
based on transcriptomic data. The purple cells represent the relative 




DBahA each perturbed nine, ten, and six hallmarks of can-
cer, respectively. The majority of the hallmarks were asso-
ciated with one pathway; however, “resisting cell death” for 
BbF was associated with five pathways, “avoiding immune 
destruction” for BkF associated with six pathways, and 
“sustained proliferative signaling” for DBahA associated 
with five pathways. BghiP activated “deregulating cellular 
energetics” with one pathway, and Chr and IP did not acti-
vate any hallmarks of cancer.
Differences in the hepatic response relative 
to BaP Figure 4b shows a range of cellular processes and 
functions such as apoptosis, retinoic acid receptor (RAR) 
signaling, and circadian rhythm that were not perturbed 
following exposure to BaP, but were for at least one of 
the other PAHs. A few of these pathways were altered in 
response to more than one PAH, including cell cycle, wing-
less integration 1 (WNT) signaling, antigen processing and 
presentation, amino acid metabolism, steroid biosynthesis, 
and melatonin degradation. PAH-specific cellular responses 
were also noted, and they included cell cycle and apopto-
sis signaling for BbF, immune and inflammatory response 
(B cell receptor signaling (BCR), antigen processing and 
presentation, immune cell communication, cytotoxic T cell 
signaling, immune-mediated apoptosis) for BkF, and circa-
dian rhythm for DBahA.
Pulmonary transcriptional response
A robust transcriptomic response was observed in lungs 
compared to forestomach and liver for most of the PAHs. 
Hierarchical cluster analysis was conducted using 2324 
DEGs that were differentially expressed in at least one dose 
group of at least one PAH. Consistent with the observations 
in the forestomach and liver, transcriptomic patterns were 
unique in the lungs, exhibiting separate clustering of each 
Fig. 4  Liver a honeycomb dia-
gram showing direction of regu-
lation of pathways commonly 
enriched for by BaP and other 
PAHs. Orange honeycombs 
represent pathways that are pre-
dicted to be activated based on 
the direction of regulation of the 
genes, and blue cells represent 
those predicted to be inhibited. 
Black cells represent those in 
which 50 % of the genes indi-
cate activation and 50 % of the 
genes indicate inhibition. White 
cells represent pathways not 
significant. b Pathways enriched 
for by at least one PAH and not 
by BaP. Each column represents 
a dose group for the denoted 
PAH, and each row represents a 
gene. All colored cells represent 
genes with fold change ≥1.5 




PAH along with their dose groups (Fig. 5a). Three main 
branches were observed: BkF, Chr, and BghiP were clus-
tered on branches 1, 2, and 3, respectively, BaP, DBahA, 
and BbF on branch 4A, and IP and BaA on 4B. Analysis 
of all DEGs for commonalities among the PAHs by VENN 
analysis revealed no genes in common to all PAHs studied. 
The number of DEGs in common between BaP and the 
other PAHs was 28 for BaA, 145 for BbF, 13 for BghiP, 28 
for BkF, 6 for Chr, 126 for DBahA, and 32 for IP (Fig. 5b). 
NextBio meta-analysis of all of the DEGs from the high-
dose groups of each PAH revealed that DBahA and BbF 
were the most correlated with the transcriptomic changes 
induced by BaP, followed by BkF and BaA. Consistent 
with the observations in forestomach and liver, Chr was 
negatively correlated with BaP (green bar) (Fig. 5c).
Similarities in the pulmonary response relative 
to BaP Although BaP induced a robust pulmonary transcrip-
tomic response, the main categories of pathways and processes 
perturbed in the lungs were the same as those in forestomach 
and livers, with the exception of alterations in homeostasis 
(Fig. 5d). However, subcategories of pathways and processes 
varied. For example, for DNA damage response, BaP-induced 
DEGs were associated with apoptosis, cell cycle, and p53 sign-
Fig. 5  Lung a hierarchical cluster analysis comparing pulmonary 
gene expression data from adult male Muta™Mouse exposed to three 
doses (low—L, medium—M, high—H) of eight PAHs. Branches are 
color coded for PAH treatment. Genes were included if they reached 
significance (FDR P ≤ 0.05, fold change ±1.5 in either direction) in 
at least one treatment group. Groups represent an average of all mice 
in one group. b Table of pulmonary DEGs common in at least one 
dose group. Cells highlighted in gray represent the total number of 
DEGs for that PAH. c Degree of correlation between BaP DEGs in 
the lung and DEGs for each PAH in the lung using the NextBio Meta-
analysis tool. The height of each vertical bar represents the degree 
of correlation between the PAH and BaP [−log(P value)], which is 
associated with the directionality of the gene expression changes. Red 
color denotes positive correlation with BaP, and green color denotes 
negative correlation. d All pathways significantly enriched for by BaP 
in the lung and the commonalities with other PAHs. Each column 
represents a dose group for the denoted PAH, and each row repre-
sents a gene. All colored cells represent genes with fold change ≥1.5 
in either direction. e Perturbation of the hallmarks of cancer, emerg-
ing hallmarks, and enabling characteristics by each PAH in the lung 
based on transcriptomic data. The purple cells represent the relative 




aling. Altered cell signaling was enriched and included several 
subcategories of pathways and processes: angiogenesis, neu-
ronal signaling, lipid signaling, as well as WNT, PPAR, RXR, 
PTEN, phosphoinositide-3-kinase protein kinase B (PI3K/
AKT), insulin-like growth factor 1 (IGF-1), AHR, and platelet-
derived growth factor (PDGF) signaling pathways. The most 
significantly altered immune and inflammatory pathways were 
B cell receptor signaling, complement activation, innate-to-
adaptive immune cell communication, and interleukin signal-
ing. Circadian rhythm was the only pathway perturbed under 
the category “homeostasis.” In the lungs, BaP exposure acti-
vated pathways associated with all ten hallmarks of cancer 
(Fig. 5e). The number of pathways associated with each hall-
mark ranged from one to ten pathways; the ten pathways were 
associated with “sustained proliferative signaling”.
Although 16 pathways or biological processes were per-
turbed by BaP and at least one other PAH, the collective 
pathway response induced by the other PAHs varied sig-
nificantly, which is clearly shown in Fig. 6a. For example, 
apoptosis, cell cycle, and p53 signaling pathways reflecting 
DNA damage response were also induced by BbF, DBahA, 
and IP. Of the 11 distinct pathways in the “altered cell sign-
aling” category perturbed in response to BaP, only seven 
were significant following BbF exposure, and less than four 
were altered in response to the other PAHs. Similarly, only 
BbF, BaA, and IP showed significant changes in at least 
three of the four pathways associated with immune and 
inflammatory response. In addition, among the commonly 
regulated pathways, the directionality of change in path-
ways reflecting their functionality was different for each 
Fig. 6  Lung a honeycomb diagram showing direction of regulation 
of pathways commonly enriched for by BaP and other PAHs. Orange 
honeycombs represent pathways that are predicted to be activated 
based on the direction of regulation of the genes, and blue cells rep-
resent those predicted to be inhibited. Black cells represent those in 
which 50 % of the genes indicate activation and 50 % of the genes 
indicate inhibition. White cells represent pathways not significant. 
b Pathways enriched for by at least one PAH and not by BaP. Each 
column represents a dose group for the denoted PAH, and each row 
represents a gene. All colored cells represent genes with fold change 
≥1.5 in either direction (color figure online)
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PAH. A few examples of this include p53 signaling (BaP↑, 
BaA↓), apoptosis (BaP↑, BkF↓, Chr↓), and complement 
system activation (BaP↓, BbF↑). For several others, it 
was difficult to determine directionality: apoptosis (BaP↑, 
BaA↕, IP↕), p53 signaling (BaP↑, BbF↕, DBahA↕, IP↕), 
angiogenesis (BaP↑, Chr↕), Wnt signaling (BaP↑, BbF↕, 
BghiP↕, DbahA↕), neuronal signaling (BaP↑, BbF↕, BkF↕, 
DBahA↕), lipid signaling (BaP↑, BbF↕), and complement 
activation (BaP↑, Chr↕). The other PAHs each affected 
pathways associated with at least eight hallmarks of can-
cer, with the exception of BghiP that induced two with one 
pathway each. BbF perturbed the greatest magnitude (num-
ber of pathways) of response with two hallmarks associated 
with 12 significant pathways, “resisting cell death” and 
“sustained proliferative signaling” and one hallmark asso-
ciated with eleven significant pathways, “activating inva-
sion and metastasis.”
Fourteen upstream regulators were associated with the 
genes altered in response to three of the PAHs and BaP in 
lungs (Online Resource 4), including endogenous mam-
malian chemicals, protein complexes and groups, enzymes, 
growth factors, ligand-dependent nuclear receptors, and 
transcription regulators. All of these regulators (except 
β-estradiol) were connected by a single node—p53—a 
transcription factor commonly implicated in PAH-induced 
carcinogenesis.
Differences in the pulmonary response relative 
to BaP Antibody production, circadian rhythm, calcium 
signaling, xenobiotic metabolism, G protein signaling, and 
cytoskeletal organization were among the pathways altered 
following exposure to PAHs that were not perturbed by 
BaP exposure (Fig. 6b). Although these differences were 
not found for BaP, pathways such as cytoskeletal organi-
zation, immune-mediated apoptosis, circadian rhythm, and 
calcium signaling were perturbed in response to more than 
three PAHs, potentially suggesting a non-BaP-like response 
shared by other PAHs. Some of these pathways were unique 
to a single PAH, including: exocytosis signaling, RNA 
processing, and antibody production for BaA; altered cell 
signaling (ABC transporters, protein kinase A signaling, 
thrombin signaling, endothelin signaling, 14-3-3 signaling, 
inhibitor of P70 S6 kinase (P70S6KI) signaling, hypoxia 
signaling, ephrin receptor signaling), acute phase response, 
extracellular membrane interactions, and inflammatory 
response for BbF; altered metabolism (retinol metabo-
lism, melatonin degradation, steroid biosynthesis) for BkF; 
altered cell signaling (cell-to-cell signaling, nitric oxide 
signaling) and cytoskeletal reorganization (focal adhesion 
kinase (FAK) signaling, paxillin signaling) for Chr; trans-
forming growth factor β (TGFβ) signaling for DBahA; and 
altered cell signaling (aldosterone signaling, ubiquitination) 
and NLR signaling for IP.
Apical responses to PAHs in the lungs
Since the lung transcriptome was the most affected of the 
three tissues studied, in the present study, we evaluated 
DNA adduct formation, lacZ mutant frequency, and EROD 
activity for lungs. The purpose is to exclusively compare 
the PAH-specific responses for these apical endpoints 
within the most affected tissue.
Pulmonary DNA adduct formation
The presence of bulky DNA adducts indicates the potential 
mutagenicity of exposure to a chemical. Using the 32P-post-
labeling technique, DNA adducts were measured in mouse 
lungs following exposure to each of the individual PAHs 
(Fig. 7a). No adducts were detected in controls treated with 
vehicle only. The DNA adduct profiles obtained are shown 
in Online Resource 5. Although every PAH tested induced 
adducts in all dose groups, the adduct levels for all of these 
PAHs were lower than BaP. BaA, BbF, BghiP, and DBahA 
showed a dose-dependent increase in adduct levels similar 
to BaP; however, the levels of DNA adducts formed fol-
lowing exposures to BkF, Chr, and IP did not show dose-
specific trends. It is important to note that the DNA adduct 
spots for the BghiP and IP samples were close to the origin 
on the thin-layer chromatography plate, which may have 
impacted quantitation. Thus, the observed increases in the 
adduct levels for these two PAHs are classified as semi-
quantitative (Online Resource 5).
Pulmonary lacZ mutant frequency
A dose-dependent increase in pulmonary lacZ mutant fre-
quency compared to vehicle controls was observed for 
BaP (Labib et al. 2012) and DBahA (Fig. 7b). Signifi-
cant increases in lacZ mutant frequencies were observed 
in at least one dose group of BbF and BkF (ANOVA: 
P ≤ 0.0001), and BghiP and IP (ANOVA: P ≤ 0.01). 
LacZ mutant frequency was marginally increased for BaA 
and Chr despite the presence of DNA adducts (ANOVA: 
P ≤ 0.1).
EROD enzymatic activity analysis
We measured enzymatic activity of CYP1A1 via the 
EROD assay in the lungs of mice exposed to all of the 
PAHs (Fig. 7c). A dose-dependent increase in the activity 
of CYP1A1 was observed for BaP, BaA, BbF, BghiP, Chr, 
DBahA, and IP. BkF also showed an increase in EROD 
activity, but there was no apparent dose–response. BbF 
showed the maximum activity at the high dose with a 43.8-
fold increase compared to vehicle controls. BghiP was the 
lowest inducer at all doses and showed maximum activity 
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at the high dose with 2.8-fold increase compared to vehicle 
controls.
BMD analysis
The relative potency of the PAHs was calculated using 
BMD analysis. BMD and BMDL values for each apical 
endpoint in the lung tissue (DNA adduct formation, lacZ 
mutant frequency, and EROD activity) and for the number 
of hallmarks of cancer activated by each PAH in the fores-
tomach, liver, and lung were obtained. BMD values derived 
from gene expression data were compared to BMDs of the 
apical endpoints (Fig. 7d–i). In general, the BMD models 
were able to fit the dose–response relationships exhibited 
by the apical endpoints and the hallmarks of cancer for the 
eight PAHs studied. Visual inspection of the curves con-
firmed this, and BMD/BMDL ratios <4 were obtained for 
all datasets.
The BMD values derived from the pulmonary DNA 
adduct data ranged from 1.5 mg/kg-bw/day for DBahA to 
15.4 mg/kg-bw/day for BaP. The BkF and Chr data could 
not be modeled. In order of lowest to highest BMD values: 
DBahA < BghiP < BbF < BaA < IP < BaP; however, the 
differences between BMD and BMDL (lower confidence 
intervals) for each PAH suggest that the potencies are not 
statistically significant, with the exception of DBahA, 
which is substantially lower. The BMD values derived from 
the lacZ mutant frequency data ranged from 0.5 mg/kg-bw/
day for DBahA to 23.5 mg/kg-bw/day for BghiP, compared 
to 2.6 mg/kg-bw/day for BaP. The BaA, BbF, BkF, and Chr 
Fig. 7  a DNA adduct formation, b lacZ mutant frequency, and c 
EROD activity in the lungs from Muta™Mouse sub-chronically 
exposed to BaP, BaA, BbF, BghiP, BkF, Chr, DBahA, and IP. Levels 
of PAH-DNA adducts were determined using the nuclease P1 enrich-
ment version of the 32P-post-labeling method. Data are represented 
as average ± SEM. Average lacZ mutant frequency was determined 
using the P-gal-positive selection assay. Values shown are average 
frequencies × 105 ± SEM. *P < 0.1, **P < 0.01 compared to vehi-
cle controls. EROD activity was determined by pooling the tissue 
for all mice in each dose group. No significance can be calculated. 
DNA adduct and lacZ mutant frequency for BaP were previously 
reported (Labib et al. 2012). ND not detected. d–i Charts of BMD 
(−BMDL) values in mg/kg-bw/day for each PAH based on data for d 
DNA adducts, e lacZ mutant frequency, and f EROD activity, and the 
number of hallmarks of cancer associated with the pathways in the g 




data could not be modeled. In order of lowest to highest 
BMD values: DBahA < BaP < IP < BghiP; however, the 
BghiP and IP lower confidence intervals overlap. The BMD 
values derived from the pulmonary EROD data ranged 
from 0.06 mg/kg-bw/day for DBahA to 48.2 mg/kg-bw/day 
for BaP. The BbF and BkF data could not be modeled. In 
order of lowest to highest BMD values: DBahA < IP < C
hr < BghiP < BaA < BaP. Note that the lower confidence 
intervals for DBahA and IP overlap.
The BMDL values derived from the hallmarks of can-
cer in the forestomach tissue ranged from 25.3 mg/
kg-bw/day for BghiP to 150.0 mg/kg-bw/day for Chr, 
compared to 56.5 mg/kg-bw/day for BaP. The forestom-
ach data for BaA, DBahA, and IP could not be modeled 
because of lack of response at the transcriptional level. 
In order of lowest to highest, the BMDL values were 
BghiP < BaP < BkF < BbF < Chr; however, the lower 
confidence intervals overlap for all PAHs. The BMD val-
ues derived from the hallmarks of cancer in the liver 
ranged from 17.0 mg/kg-bw/day for DBahA to 71.9 mg/
kg-bw/day for BaP. The data for BaA and BghiP could 
not be modeled due to lack of model fit, and the data for 
Chr and IP could not be modeled due to lack of response. 
In order of lowest to highest, the BMD values were 
DBahA < BkF = BbF < BaP; however, the lower confi-
dence intervals for all PAHs except for DBahA overlap. 
The BMD values derived from the hallmarks of cancer in 
the lung ranged from 7.53 mg/kg-bw/day for DBahA to 
139.2 mg/kg-bw/day for Chr, compared to 34.5 mg/kg-bw/
day for BaP. In order of lowest to highest, the BMD values 
were DBahA < BkF < IP < BbF < BaP < BaA < Chr. Note 
that the lower confidence intervals for all PAHs overlap 
except for DBahA. The data for BghiP could not be mod-
eled due to lack of fit.
Discussion
BaP is commonly accepted as a reference PAH in the esti-
mation of excess lifetime cancer risk posed by genotoxic 
PAHs or PAH-containing mixtures (CCME 2010; EFSA 
2008; Health Canada 2010). This is primarily based on the 
hypothesis that the genotoxic PAHs, such as those studied 
herein, act via similar modes/mechanisms of action. How-
ever, the results from several recent studies have challenged 
this paradigm (Jung et al. 2013; Song et al. 2012; Tilton 
et al. 2015). In the present study, we tested this hypothesis 
using a toxicogenomic approach that enables investigation 
of global changes in the expression of genes and associated 
pathways in a tissue in a single experiment. We specifi-
cally characterized the gene expression changes occurring 
in mouse forestomach, liver, and lung following exposure 
to seven individual PAHs (CCME 2010) and compared 
the expression changes in these tissues to those induced 
by exposure to BaP in previous studies (Labib et al. 2012, 
2013; Malik et al. 2013). Systematic bioinformatics anal-
ysis of all DEGs and pathways perturbed in response to 
each individual PAH revealed three major features: (1) all 
PAHs induce expression changes in genes associated with 
a wide variety of carcinogenic pathways, processes, and 
functions, (2) all PAHs induce changes in the expression of 
genes implicated in DNA damage response conventionally 
described for genotoxic PAHs; however, the response var-
ies significantly from PAH to PAH in the number of DEGs 
and the magnitude of the response (level of expression of 
each gene), and (3) PAHs induce transcriptional responses 
that are PAH- and tissue-specific. The significant differ-
ences noted in the global pathway perturbations across 
PAHs imply that, in contrast to the assumptions made in 
mixture risk assessment, the underlying toxicity pathways, 
some of which have been implicated in carcinogenesis, 
are not the same for all of the PAHs investigated and vary 
across tissues.
The accepted ways by which carcinogenic PAHs induce 
DNA damage and mutations involve: (1) induction of the 
dihydrodiol epoxide pathway catalyzed by CYP enzymes 
leading to stable pro-mutagenic DNA adducts, (2) the oxi-
dation of PAH dihydrodiols by dihydrogenases to PAH-
derived ortho-quinones leading to stable DNA adducts and 
formation of reactive oxygen species that may further con-
tribute to the DNA damage, and (3) binding and activation 
of AhR resulting in intensified transcriptional activation 
of not only CYP1A1 but also sulfotransferases and other 
conjugation enzymes, which also influence DNA adduct 
formation. The formation of DNA adducts, an immediate 
consequence of PAH metabolism, is considered an early 
key event of PAH-mediated carcinogenesis (Moffat et al. 
2015). However, several studies have shown that DNA 
adducts may not accurately predict the carcinogenic risk 
of genotoxic PAHs (Pottenger et al. 2009). For example, it 
has been shown that DNA adducts are present in most of 
the tissues of rats (Kroese et al. 2001) and mice (Zuo et al. 
2014) exposed to BaP, including the tissues that eventually 
develop cancer, as well as those that do not. Similar obser-
vations of lack of tumors in tissues showed that high lev-
els of DNA adducts following exposure to BaP were also 
noted in mice (Culp et al. 1998) and in rats (Weyand et al. 
1995). Furthermore, tissue-specific rates of CYP induction, 
levels of DNA adducts, and mutation frequencies do not 
correlate with the extent of tumor formation in the tissues 
studied (Godschalk et al. 2003). These findings suggest that 
additional factors may be involved in PAH-induced tissue-
specific oncogenesis. While Kroese et al. (2001) suggested 
that local cellular proliferation may be one such additional 
factor required for cancer development, here we show that 
perturbations of several additional biological pathways that 
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are directly favorable to carcinogenesis may be operating in 
parallel with DNA damage/mutation to influence the proba-
bility of developing tissue-specific tumors in mice (Fig. 8).
In the present study, exposure to each of the PAHs caused 
significant increases in both DNA adducts and transgene 
mutant frequency in lung compared to matched controls. 
However, considerable differences in lung responses were 
observed at the pathway level for each PAH examined. 
PAH-specific pathway changes were also observed in the 
liver and forestomach. To determine whether consideration 
of apical endpoints and perturbations in a number of key 
pathways that are favorable to cancer formation would help 
improve cancer predictivity, we compared the BMDs for 
the lung apical endpoints and genomics endpoints for each 
of the PAHs examined. The known hallmarks of cancer 
were used as a directional tool to effectively classify a wide 
variety of pathways perturbed by the PAHs into functional 
groups and to highlight the altered tissue microenvironment 
following exposure. BMD calculation for individual apical 
endpoints and cancer-specific pathways varied depending 
on the type of data considered. The DNA adduct-derived 
BMDs predicted BghiP to be the second most potent, 
which is contrary to the available literature and its recent 
classification as a PAH lacking evidence for carcinogenic-
ity by the USEPA and IARC (IARC 2010; USEPA 2011). 
These results further support the complexities related to the 
predictive value of DNA adducts for carcinogenic potency 
of PAHs discussed above. BMD values derived from the 
results of mutant frequency ranked DBahA and BaP as the 
most potent with respect to their ability to induce mutation 
in a non-transcribed transgene. BaA and Chr data could not 
be modeled due to their poor ability to induce mutation as 
observed by the lack of response. It was also not possible to 
model BkF data due to lack of dose response. However, at 
the low and medium dose, BkF did show increased mutant 
frequency. Similarly, cancer pathway-based BMDs ranked 
DBahA as the most potent PAH able to elicit hallmark 
events and Chr as the least potent, which is in line with 
IARC’s classification of Chr as a group 3 non-carcinogen 
(IARC 2010; USEPA 2011). BaP was consistently ranked 
less potent than DBahA for all endpoints considered, in 
line with the results of an earlier study that showed DBahA 
as a more potent carcinogen in rats compared to BaP (Wen-
zel-Hartung et al. 1990). The importance of the temporal 
coordination of the hallmarks of cancer should be noted. 
The activation of angiogenesis or invasion and metastasis 
Fig. 8  Activation or suppression of cell signaling pathways in sup-
port of pulmonary carcinogenic transformation. This schematic 
describes the contribution of each PAH to the carcinogenic mode of 
action in the form of the hallmarks of cancer. These signaling events 
are vital to the progression of cancer and are occurring in parallel to 
the genotoxic MOA key events. The order of the hallmarks in the fig-
ure does not reflect any temporal coordination or cooperation with the 
existing key events. BaP’s carcinogenic MOA key events are shown 
in blue font (color figure online)
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are later events in tumor progression; however, identifica-
tion of perturbations in related signaling pathways at early 
stages may enhance the tumor predictivity when considered 
in conjunction with conventional toxicological endpoints. 
Although, it is not general practice to derive BMDs for 
DNA adducts, mutations (e.g., lacZ mutant frequency), or 
gene pathways for regulatory purposes, in the absence of 
rodent cancer bioassay data, BMDs for these toxicological 
endpoints may serve to set regulatory limits that would pro-
tect against effects that are mechanistically or empirically 
linked to carcinogenesis and prioritize compounds for fur-
ther testing by long-term cancer bioassays. Recently, in a 
comprehensive case study, Moffat et al. (2015) compared 
BMDs derived from traditional cancer bioassays and those 
derived from pathway-based analyses indicative of carcino-
genesis in BaP-exposed tissues. The authors showed a high 
concordance between the points of departures derived from 
both apical and gene expression endpoints, as well as can-
cer bioassays for BaP. However, it is not possible to make 
direct comparisons between the BMDs derived from cancer 
bioassays and the results from the present study since not 
all the PAHs examined have cancer bioassay results avail-
able (IARC 2010). Although further studies are needed to 
conclusively demonstrate the use of such non-cancer bio-
assay data for regulatory purposes, in the immediate term, 
the gene expression results obtained from the present and 
the study by Moffat et al. can be used to support the deci-
sion to use non-cancer data in a regulatory setting and to 
help reduce the uncertainties associated with that approach. 
Collectively, these results suggest that depending on the 
endpoint investigated, the potency ranking of each of these 
PAHs, including BaP, will differ for each tissue; a detailed 
knowledge of pathway perturbations will reduce the uncer-
tainties involved in making such predictions of future 
carcinogenesis and will increase the accuracy of these 
rankings.
With the exception of BghiP, we observed that the key 
pathways involved in DNA adduct formation and DNA 
damage in lungs were all activated in response to the indi-
vidual PAH exposures. These results suggested that six of 
the PAHs tested induce DNA damage responses similar to 
those observed in response to BaP. However, activation of 
several other cellular signaling pathways indicative of hall-
marks of cancer, including neuronal signaling (required for 
activation of invasion and metastasis), activation of angio-
genesis (required for blood vessel formation in tumors), 
activation of PI3 K/AKT signaling pathway (involved in 
resisting cell death), cell cycle progression (required for 
cellular proliferation in the presence of damaged DNA), 
circadian rhythm signaling (associated with the evasion 
of growth suppressors), inhibition of PPARγ signaling 
(required for inhibition of neoplastic growth of cancer 
cells), avoiding immune destruction, and tumor-promoting 
inflammation, varied between the PAHs. The other path-
ways uniquely altered only in response to congener PAHs 
in the present study, such as calcium signaling (BaA, BbF, 
and Chr), endocytosis (BbF, Chr, and DBahA), chemokine 
signaling (BbF, BghiP, and BkF), and cytoskeletal reorgani-
zation (BbF, BkF, Chr, and IP), have previously been linked 
to BaP exposure (Ba et al. 2014; Laupeze et al. 2002; 
Mayati et al. 2012; van Grevenynghe et al. 2003). For 
example, G protein-coupled receptor signaling mediates 
alterations in calcium signaling in endothelial HMEC-1 
cells and human kidney HEK293 cells following exposure 
to BaP (Mayati et al. 2012), as demonstrated by the inhibi-
tion of BaP-induced signaling in the presence of suramin, 
a potent inhibitor of G protein. Chemokine signaling 
induced by BbF, BghiP, and BkF was observed following 
BaP-induced inflammation in primary human macrophages 
(Lecureur et al. 2005; Sparfel et al. 2010). Similarly, endo-
cytic function is inhibited in macrophages, and dendritic 
cells derived from human monocytes exposed to BaP (Lau-
peze et al. 2002; van Grevenynghe et al. 2003). However, 
the implications of these pathways in cancer formation in 
lungs are not clear. Thus, it is not apparent whether a com-
bination of DNA adduct formation, mutation induction, 
and the perturbation of pathways mentioned above is suf-
ficient to trigger cancer formation following exposure to 
PAHs. One possibility is that the PAHs that induced low 
levels of DNA damage or mutations and subtle responses 
at the pathway levels could be acting as tumor promoters 
rather than initiators of cancer. For instance, it is known 
that altered calcium signaling helps sustain cellular pro-
liferation and foster metastatic environment (Prevarskaya 
et al. 2011; Resende et al. 2013), and defective endocyto-
sis has been linked to increased metastatic function in can-
cer cells (Mosesson et al. 2008). Cytoskeletal organization 
has been linked to metastasis and invasion of early tumor 
cells (Donald et al. 2001), and it is known that BaP expo-
sure promotes cell migration and invasion in both in vivo 
and in vitro models of human hepatocellular carcinoma (Ba 
et al. 2014). This may be required for expansion of geneti-
cally damaged cells and subsequent cancer formation. 
Inflammation involving chemokine signaling is also pro-
posed to promote conditions conducive to cancer formation 
in genotoxic, as well as in non-genotoxic, scenarios (Lu 
et al. 2006). Thus, in addition to the DNA damage response 
pathways induced by BaP and the other PAHs examined, 
activation of distinct signaling pathways induced by the 
other PAHs suggests greater contribution of alternative car-
cinogenic mode/mechanisms.
In addition to the induction of cancer-related path-
ways, the results of the present study demonstrate that 
the tissue-specific transcriptional responses to PAHs 
are distinct, suggesting that the carcinogenic potency 
of each individual PAH will vary based on the type of 
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tissue investigated. Of the forestomach, liver, and lung 
tissues, the greatest response at the transcriptional 
level was induced in the lung, which we previously 
showed for BaP in both acute exposure (B6C3F1 mice 
orally exposed to BaP for 3 days with sample collec-
tion 4 h post-exposure) (Halappanavar et al. 2011) and 
sub-chronic studies (Labib et al. 2012, 2013). Indeed, 
the BMD values for transcriptional pathways associ-
ated with the hallmarks of cancer for seven of the eight 
PAHs indicated that the pulmonary response was more 
sensitive than the liver and forestomach (BaP, BaA, BbF, 
BkF, Chr, DBahA, and IP). For BghiP, only the fores-
tomach data could be modeled, possibly indicative of 
lower potential for adverse outcomes in the lung and 
liver compared to the forestomach for this PAH. Simi-
lar observations of enhanced pulmonary response were 
noted in mice exposed to oral BaP in studies conducted 
by Halappanavar et al. (2011) and Harrigan et al. (2006). 
Other recent studies have also shown tissue-specific gene 
expression changes in a multi-tissue analysis following 
BaP exposure (Zuo et al. 2014). One of the explanations 
for the observed tissue-specific discrepancies could be 
the different rates of metabolism, clearance, and trans-
location or tissue distribution of these PAHs from the 
targeted tissues. It is a possibility that some PAHs, such 
as DBahA and BbF, are quickly distributed to distant 
organs (e.g., lungs) from the forestomach (site of con-
tact), which may result in reduced impact on the fores-
tomach. This in turn may induce differential responses 
at the molecular level that are related to the likelihood of 
eventual cancer formation.
Conclusions
The present study explored the validity of the assump-
tion that BaP is an acceptable reference PAH for gen-
otoxic, carcinogenic PAHs by examining the global 
gene expression changes in three separate tissues. Our 
results showed that all of the PAHs investigated were 
able to induce genotoxicity in a dose-dependent man-
ner. However, these results were not comparable with 
the known relative potencies calculated based on BaP 
as a reference chemical (CCME 2010). The results also 
revealed a response at the transcriptional level follow-
ing exposure to the PAHs that varied according to agent, 
dose, and tissue. Moreover, the gene expression results 
clearly demonstrated that each PAH induces molecular 
alterations (signaling pathways) related to carcinogen-
esis that are distinct from those observed for BaP, thus 
contradicting the assumption that they all act through 
similar mechanisms. We show differences in the abil-
ity of PAHs to induce major key events, as well as other 
molecular changes related to carcinogenesis, which sug-
gests that the relative potency approach, which is esti-
mated based on current default assumptions, may not be 
accurate. These distinct tissue-specific transcriptional 
responses are indicative of the need to exercise caution 
when deriving potency equivalence factor (PEF) values; 
depending on what endpoint/tissue is evaluated in com-
ing up with a PEF value, these differences could lead 
to overestimation or underestimation of the PEF, which 
would result in overestimation or underestimation of the 
total risk estimate.
Thus, the results of the present study show that BaP 
alone may not accurately reflect the toxicity imparted by 
other PAH congeners and suggest that consideration of 
toxicity induced by more than one PAH be used to repre-
sent the class of PAHs. Finally, moving forward, an inte-
grated approach that involves multiple endpoints, includ-
ing genomics, and multiple tissues may help increase the 
accuracy of the assay-derived relative potencies for each 
PAH and the predictive potential of the relative potency 
approach.
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